2024-510856-11-00CompletedPhase 1
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Jan 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 22 May 2024
- Start date
- 31 Oct 2024
- Lead sponsor
- Bayer AG
- EU CT number
- 2024-510856-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 15
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.